Objective To explore the effect of low molecular weight heparin combined with aspirin on efficacy and maternal and infant outcomes in patients with preeclampsia.
Methods Totally 200 patients with preeclampsia were selected and randomly divided into heparin plus aspirin group and aspirin group, with 100 cases in each group. The aspirin group was given aspirin and symptomatic treatment, while the heparin plus aspirin group was given low molecular weight heparin treatment on the basis of the aspirin group. The coagulation function indexes D-dimer (D-D), plasma fibrinogen (FIB), blood pressure systolic blood pressure (SBP), diastolic blood pressure (DBP), the ratio of maximum systolic blood flow velocity of uterus and umbilical artery to end-diastolic blood flow velocity (S/D), maternal and infant outcomes and adverse reactions were compared between the two groups.
Results After treatment, D-D, FIB, SBP, DBP, S/D values of uterus and umbilical artery in both groups were significantly lower than those before treatment, while D-D, FIB, SBP, DBP, S/D values of uterus and umbilical artery in the heparin plus aspirin group were lower than those in the aspirin group (P < 0.05), and the incidence rate of adverse maternal and infant outcomes in the heparin plus aspirin group was significantly lower than that in the aspirin group (P < 0.05). There was no significant difference in the incidence rate of adverse reactions between the two groups (P>0.05).
Conclusion Low molecular weight heparin combined with aspirin can effectively improve the blood coagulation function, blood pressure, blood flow status of uterine and umbilical artery in patients with preeclampsia.
DownLoad: